MA53275A - Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine - Google Patents

Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine

Info

Publication number
MA53275A
MA53275A MA053275A MA53275A MA53275A MA 53275 A MA53275 A MA 53275A MA 053275 A MA053275 A MA 053275A MA 53275 A MA53275 A MA 53275A MA 53275 A MA53275 A MA 53275A
Authority
MA
Morocco
Prior art keywords
carboxamides
ubiquitin
protease inhibitors
specific protease
specific
Prior art date
Application number
MA053275A
Other languages
English (en)
Inventor
Justin Caravella
Jennifer R Downing
David J Guerin
Stephanos Ioannidis
Hongbin Li
Pui Yee Ng
Tatiana Shelekhin
Zhongguo Wang
Mary-Margaret Zablocki
Original Assignee
Valo Early Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/046061 external-priority patent/WO2019032863A1/fr
Application filed by Valo Early Discovery Inc filed Critical Valo Early Discovery Inc
Publication of MA53275A publication Critical patent/MA53275A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA053275A 2018-08-09 2019-08-08 Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine MA53275A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862716744P 2018-08-09 2018-08-09
PCT/US2018/046061 WO2019032863A1 (fr) 2017-08-11 2018-08-09 Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine
US201962788204P 2019-01-04 2019-01-04
US201962805118P 2019-02-13 2019-02-13

Publications (1)

Publication Number Publication Date
MA53275A true MA53275A (fr) 2021-09-15

Family

ID=69457770

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053275A MA53275A (fr) 2018-08-09 2019-08-08 Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine

Country Status (12)

Country Link
US (1) US12162888B2 (fr)
EP (1) EP3833661A1 (fr)
JP (1) JP2021534123A (fr)
KR (1) KR20210068010A (fr)
CN (1) CN112867712B (fr)
AU (1) AU2019319907B2 (fr)
BR (1) BR112021002408A2 (fr)
CA (1) CA3108676A1 (fr)
IL (1) IL280486B2 (fr)
MA (1) MA53275A (fr)
MX (1) MX2021001376A (fr)
WO (1) WO2020033707A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3833441A1 (fr) 2018-08-09 2021-06-16 Valo Early Discovery, Inc. Inhibition de la déubiquitinase usp25 et usp 28
EP3897670A4 (fr) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs
CN111909181B (zh) * 2019-05-09 2023-02-07 杭州普济远成生物医药科技有限公司 一类泛素化特异性蛋白酶抑制剂及其制备方法与应用
CN111943879A (zh) * 2020-08-03 2020-11-17 南通大学 一种（3s，4r）3-氨基-4（甲氧基甲基）吡咯烷-1-甲酸叔丁酯及其合成方法
CN112898314A (zh) * 2020-11-06 2021-06-04 刘丽萍 去泛素化酶抑制剂的制备与应用
US20250282783A1 (en) * 2021-12-22 2025-09-11 Stablix, Inc. Protein stabilizing compounds containing usp28 and/or usp25 targeting ligands
JP2025516222A (ja) * 2022-04-28 2025-05-27 杭州普済遠成生物医薬科技有限公司 脱ユビキチン化酵素阻害剤及びその応用
KR20250004854A (ko) * 2022-04-29 2025-01-08 장슈 야홍 메디텍 코퍼레이션 리미티드 피리미딘 화합물, 이의 제조 방법 및 이의 약학적 용도
CN115246842B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类靶向去泛素化酶usp25和usp28的小分子抑制剂
WO2024114793A1 (fr) * 2022-12-01 2024-06-06 杭州普济远成生物医药科技有限公司 Forme saline et forme cristalline d'un inhibiteur de protéase spécifique de l'ubiquitination, leur procédé de préparation et leur utilisation
CN117916246A (zh) * 2022-12-01 2024-04-19 杭州普济远成生物医药科技有限公司 泛素化特异性蛋白酶抑制剂盐型、晶型及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5550800A (en) 1999-06-22 2001-01-09 School Of Pharmacy, University Of London, The Diagnosis and treatment of alzheimer's disease
EP1680431A1 (fr) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Compositions de benzothiazole et de thiazole'5,5-b!pyridine et leur utilisation comme inhibiteurs de l'ubiquitine ligase
SE0403171D0 (sv) 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
UY32443A (es) * 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
CN104856991A (zh) 2009-02-27 2015-08-26 西佳技术公司 用于治疗和预防登革热病毒感染的噻吩并吡啶衍生物
WO2012040527A2 (fr) 2010-09-24 2012-03-29 The Regents Of The University Of Michigan Inhibiteurs de déubiquitinase et leurs procédés d'utilisation
DE102012006884A1 (de) 2012-04-04 2013-10-10 Merck Patent Gmbh Cyclische Amide als MetAP-2 Inhibitoren
EP2938610A2 (fr) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibiteurs du complexe usp1/uaf1 désubiquitinase et leurs utilisations
WO2014116859A1 (fr) 2013-01-23 2014-07-31 The University Of Chicago Méthodes et compositions d'inhibition des protéines atox1 et ccs impliquées dans le transfert du cuivre
EP3148971A4 (fr) 2014-06-02 2017-10-25 Pharmakea, Inc. Inhibiteurs de déubiquitinase
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
CN108473495B (zh) * 2015-11-20 2022-04-12 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
CN109071561B (zh) 2016-02-12 2022-01-14 福马治疗股份有限公司 用作泛素特异性蛋白酶抑制剂的噻吩并吡嗪甲酰胺
CA3014192A1 (fr) 2016-02-12 2017-08-17 Forma Therapeutics, Inc. Thienopyridine carboxamides utilises comme inhibiteurs de protease specifique de l'ubiquitine
AR112468A1 (es) 2017-08-11 2019-10-30 Forma Therapeutics Inc Carboxamidas como inhibidores de proteasa específicos de ubiquitina
EP3833441A1 (fr) 2018-08-09 2021-06-16 Valo Early Discovery, Inc. Inhibition de la déubiquitinase usp25 et usp 28

Also Published As

Publication number Publication date
MX2021001376A (es) 2021-06-23
CN112867712A (zh) 2021-05-28
CA3108676A1 (fr) 2020-02-13
WO2020033707A1 (fr) 2020-02-13
KR20210068010A (ko) 2021-06-08
BR112021002408A2 (pt) 2021-05-04
US20210323975A1 (en) 2021-10-21
AU2019319907A1 (en) 2021-02-18
EP3833661A1 (fr) 2021-06-16
JP2021534123A (ja) 2021-12-09
CN112867712B (zh) 2024-07-16
IL280486A (en) 2021-03-25
AU2019319907B2 (en) 2024-09-05
US12162888B2 (en) 2024-12-10
IL280486B1 (en) 2024-09-01
IL280486B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
MA53275A (fr) Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine
EP3902802A4 (fr) Compositions pour inhiber la protéase 1 spécifique de l'ubiquitine
MA53816A (fr) Pyrrolines fusionnées qui agissent en tant qu'inhibiteurs de la protéase 30 (usp30) spécifique de l'ubiquitine
IL282103A (en) Furinones as ubiquitin-specific protease 1 inhibitors
MA49841A (fr) Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA42032A (fr) Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac
EP3692028A4 (fr) Inhibition de la peptidase 30 spécifique de l'ubiquitine
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA41291A (fr) Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
MA44725A (fr) Formulations d'un inhibiteur de lsd1
DK3529241T3 (da) Pireridinderivater som inhibitorer af ubiquitin-specifik protease 7
EP3957711C0 (fr) Composition de détergent comprenant des variants de protéase et d'amylase
EP3743424A4 (fr) Inhibiteurs d'endonucléase dépendant du cap
MA45656A (fr) Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1
EP4013496A4 (fr) Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire
MA48800A (fr) Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
EP3512839A4 (fr) Inhibiteurs de yap1 ciblant l'interaction de yap1 avec oct4
MA51202A (fr) Nouveaux dérivés de pipéridinyle utilisés en tant qu'inhibiteurs de la protéase 7 spécifique à l'ubiquitine
EP4023275A4 (fr) Liquide destiné à être atomisé
EP3331887A4 (fr) Benzodiazépines en tant qu'inhibiteurs de bromodomaines
DK4053272T3 (da) Ny serinprotease-variant
FR3048216B1 (fr) Lame d'essuyage pour balai d'essuie-glace